Citazione APA

Raedler, L. A. (2016). Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia. Am Health Drug Benefits.

Stile di citazione Chicago

Raedler, Lisa A. "Praluent (Alirocumab): First PCSK9 Inhibitor Approved By the FDA for Hypercholesterolemia." Am Health Drug Benefits 2016.

Citazione MLA

Raedler, Lisa A. "Praluent (Alirocumab): First PCSK9 Inhibitor Approved By the FDA for Hypercholesterolemia." Am Health Drug Benefits 2016.

Attenzione: Queste citazioni potrebbero non essere precise al 100%.